Brokerages Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $7.60

Shares of ProQR Therapeutics (NASDAQ:PRQR) have been given an average rating of “Buy” by the five research firms that are covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $7.60.

PRQR has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of ProQR Therapeutics in a research note on Thursday. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $6.00 to $14.00 in a research note on Tuesday, October 29th. StockNews.com lowered shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. JMP Securities reiterated a “market outperform” rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a research note on Thursday. Finally, Chardan Capital reiterated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research note on Thursday.

ProQR Therapeutics Price Performance

PRQR stock opened at $2.83 on Thursday. The company has a market capitalization of $231.15 million, a P/E ratio of -8.84 and a beta of 0.24. ProQR Therapeutics has a 12 month low of $1.61 and a 12 month high of $4.62. The firm’s fifty day simple moving average is $3.40 and its 200-day simple moving average is $2.40.

Institutional Trading of ProQR Therapeutics

Several institutional investors have recently bought and sold shares of the business. OneDigital Investment Advisors LLC lifted its holdings in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 15,550 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 7,300 shares during the last quarter. Finally, Privium Fund Management B.V. lifted its stake in ProQR Therapeutics by 4.4% in the 2nd quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock valued at $9,208,000 after buying an additional 236,279 shares in the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).